Peuranpää P, et al. - Researchers examined the risk of early pregnancy loss in IVF/ICSI with a fresh or frozen-thawed embryo transfer (ET) in presence of a low (< 1.0 μg/L) or moderately low (1.0–1.9 μg/L) serum anti-Müllerian hormone (AMH) level. They conducted a retrospective cohort study including 1,383 women undergoing their first oocyte retrieval for IVF/ICSI in Helsinki University Hospital in Helsinki, Finland, between 2012 and 2016. All associated fresh (n = 1,315) and frozen-thawed (n = 1,418) ET cycles were finished by August 2018. Measures of AMH within 12 months before the IVF/ICSI stimulation revealed, low AMH level (< 1.0 μg/L) in 235 (17.0%) women, moderately low AMH level (1.0–1.9 μg/L) in 278 (20.1%) women and normal AMH level (≥ 2.0 μg/L) in 870 (62.9%). Women with normal AMH had higher cLBR vs women with low or moderately low AMH in their first IVF/ICSI treatment as these women had more oocytes and embryos. However, there was no association of a low or moderately low serum AMH level with miscarriage, non-visualized pregnancy loss or overall early pregnancy loss rate in the IVF/ICSI treatment. These results are reassuring for couples and are valuable for assessing the overall effectiveness of IVF/ICSI treatment.